Bravyl, an investigational oral therapy from Woolsey Pharmaceuticals, was safe and lowered levels of the nerve damage biomarker neurofilament…
Articles by Lindsey Shapiro, PhD
Adding Radicava (edaravone) to riluzole prolongs survival of amyotrophic lateral sclerosis (ALS) patients by more than three months…
Increasing levels of the MIF protein may be a promising therapeutic strategy for slowing disease progression in amyotrophic lateral…
The Foundation for the National Institutes of Health (FNIH) is launching a public-private partnership to generate the largest openly available…
The ALS Multidisciplinary Clinic at the University of Cincinnati Gardner Neuroscience Institute in Ohio has been gifted $13.5 million to…
A blood biomarker of oxidative stress, a type of cellular stress implicated in amyotrophic lateral sclerosis (ALS), is significantly…
NeuroSense Therapeutics’ investigational therapy PrimeC tends to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve…
While the now-discontinued amyotrophic lateral sclerosis (ALS) therapy Relyvrio (sodium phenylbutyrate and taurursodiol) failed to show a meaningful…
Storing chemicals such as gasoline, lawn care products, and paints in a garage attached to a home was associated with…
The U.S. Food and Drug Administration (FDA) has agreed on the design of a Phase 3b trial that will test…